AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2024
Feb 21, 2024
30604_dirs_2024-02-21_0c51ecf3-ec08-495e-a1f5-365acdf99f35.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-02-16
Reporting Person: HOMCY CHARLES J (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-16 | Common Stock | M | 3760 | — | Acquired | 1231594 | Direct |
| 2024-02-16 | Common Stock | F | 1509 | $37.21 | Disposed | 1230085 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-16 | Restricted Stock Units | $ | M | 3760 | Disposed | Common Stock (3760) | Direct |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Includes 838 shares of the Issuer's Common Stock acquired by the Reporting Person on February 15, 2024 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
F3: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs.
F4: The RSUs vested with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares vested on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.